T

he 21st Century Cures Act promises to ramp up funding for biomedical research while also loosening regulations governing drugs and medical devices. Supporters say it will speed up approval of new treatments, while critics are concerned that the safety and effectiveness may be compromised.

Before a panel discussion on the law hosted by the Harvard T.H. Chan School of Public Health and STAT, Ed Silverman, STAT senior writer and Pharmalot columnist, interviewed Aaron Kesselheim, associate professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, on Facebook live. The full Q&A video is here; the panel discussion will be available here.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy